<DOC>
	<DOCNO>NCT01782937</DOCNO>
	<brief_summary>This study open-label , non-controlled study evaluate efficacy safety KHK4827 subject pustular psoriasis ( generalize ) psoriatic erythroderma . Pharmacokinetics KHK4827 also assess .</brief_summary>
	<brief_title>An Open-label , Non-controlled Study KHK4827 Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject sign voluntarily write informed consent form participate study . Subject diagnose pustular psoriasis psoriatic erythroderma . Subject receive least one previous phototherapy systemic psoriasis therapy candidate receive phototherapy systemic psoriasis therapy opinion investigator . Subject psoriatic erythroderma involve Body surface area ( BSA ) lesion &lt; 80 % baseline . Subject diagnose guttate psoriasis , medicationinduced medicationexacerbated psoriasis . Evidence skin condition time screen visit ( eg , eczema ) would interfere evaluation effect KHK4827 psoriasis . Subject active Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 high infection Subject significant concurrent medical condition laboratory abnormality , define study protocol . Subject use Ultra Violet B ( UVB ) therapy within 14 day first dose Ultra Violet A ( UVA ) ( without psoralen ) within 28 day first dose . Subject use etanercept , adalimumab , infliximab ustekinumab within 1 week , 2 week , 8 week 12 week first dose , respectively . Subject stop ustekinumab antiInterleukin ( IL ) 23 biologics therapy due lack efficacy Subject use live vaccine within 3 month first dose Subject previously use antiIL17 biologic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>